From Venom to Vitality: The Bronx Doctor Who Unlocked the Potential of GLP-1
Long before the world was captivated by the meteoric rise of weight-loss and diabetes treatments like Ozempic, a physician working at a Veterans Affairs hospital in the Bronx was conducting research that would eventually redefine modern medicine. His subject? The potent, mysterious venom of a desert-dwelling lizard.
In 1992, Dr. John Eng, an endocrinologist at the James J. Peters VA Medical Center, made a discovery that would serve as the cornerstone for a new era of metabolic therapy. By isolating a unique molecule from the venom of the Gila monster—a large, venomous lizard native to the southwestern United States and northwestern Mexico—Dr. Eng helped pave the way for the development of drugs that are now household names.
The Problem with Human Biology
To understand the significance of Dr. Eng’s work, one must understand the challenge of the GLP-1 hormone. Scientists have long known that the human body produces a hormone called GLP-1, which is critical for stimulating insulin production when blood sugar levels rise. However, natural human GLP-1 breaks down within minutes, making it incredibly difficult to harness as a therapeutic drug.
While working at the VA, Dr. Eng discovered that the Gila monster’s venom contained a molecule he named “exendin-4.” Crucially, this molecule acted on the same GLP-1 receptors in the body as the human hormone, but with one life-changing difference: it was remarkably stable and remained active in the bloodstream for a significantly longer period.
A Path to Clinical Reality
The road from a laboratory petri dish to a pharmacy shelf is rarely easy. After identifying the potential of exendin-4, Dr. Eng licensed the technology to Amylin Pharmaceuticals. The company successfully developed a synthetic version of the molecule, known as exenatide.
In 2005, the U.S. Food and Drug Administration (FDA) approved exenatide, marketed as Byetta. It became the first GLP-1 receptor agonist ever brought to market, proving that targeting this specific biological pathway could effectively treat type 2 diabetes. This breakthrough served as the “proof of concept” for the entire class of drugs that followed.
Separating Fact from Fiction: Is Ozempic Made of Venom?
While Dr. Eng’s work is a vital chapter in the story of modern medicine, it is a common misconception that current drugs like Ozempic are derived directly from lizard venom.
Ozempic contains semaglutide, a synthetic medicine developed by modifying the human GLP-1 hormone structure to ensure it lasts long enough in the body. However, the scientific foundation for semaglutide—and the massive industry of GLP-1 receptor agonists—is built squarely on the biological lessons learned from Dr. Eng’s Gila monster research.
A Legacy of Scientific Curiosity
The story of Dr. John Eng is a testament to the idea that revolutionary breakthroughs can originate in the most unlikely of places. What began as a focused investigation into a desert lizard’s venom eventually provided the keys to addressing one of the most pressing public health crises of our time: the global diabetes and obesity epidemic.
Today, as millions of patients worldwide benefit from these treatments, the medical community continues to look back at that Bronx VA laboratory, where a persistent researcher proved that nature often holds the solutions to our most complex medical challenges.
Disclaimer: This article is based on publicly available research, scientific literature, and reports about Dr. John Eng and the development of GLP-1-based medicines. The publisher does not independently verify all historical accounts or research interpretations mentioned in the source material.
